← Research / Cognition
Cognition

Reversing Cognitive Decline & Brain Fog

Reversal of Cognitive Decline and Brain Fog Using Exact Specified Dosages of Semax, Alpha GPC, MOTS-C, NAD+, and Targeted Nutritional Support with Lifestyle Interventions in a Scopolamine-Induced Cognitive Impairment Murine Model
Preclinical · Murine model·6 min read
Educational summary. This describes a preclinical, animal-model (murine) research protocol. It is not medical advice, a dosing recommendation, or a claim about any Milky Way product, and it has not been evaluated by the FDA. Do not self-administer protocols; consult a licensed healthcare provider.

Abstract

This study evaluates a multi-pathway neuroprotective and mitochondrial-restorative protocol for reversing cognitive decline and brain fog using exact specified dosages in adult male C57BL/6 mice with scopolamine-induced cognitive impairment, a validated model of cholinergic deficit, hippocampal dysfunction, brain fog-like memory impairment, and reduced neuroplasticity. Following scopolamine administration and confirmation of the phenotype (impaired novel object recognition, reduced spontaneous alternation in Y-maze, and elevated oxidative stress at 7 days), animals received the precise protocol for 12 weeks: Semax 400 mcg (subq) daily, Alpha GPC 300 mg (split dose 150 mg 2× per day) orally, MOTS-C 5 mg (subq) twice per week (Mondays and Thursdays, morning), NAD+ 25 mg (subq) mornings, Omega-3 4 g daily orally, Zinc picolinate 30 mg daily orally, Magnesium glycinate 400 mg daily orally, D3 5000 IU daily orally, K2 200 mcg daily orally, Ubiquinol 200 mg daily orally, Chromium 200 mcg daily orally, Selenium 200 mcg daily orally, Methylated B Complex daily orally, carnivore diet, 1 mile walk after the largest meal of the day at a 16 minute pace, 18:6 fasting, and 4 L water with electrolytes daily. Primary outcomes included cognitive performance (novel object recognition and Y-maze) and neuroplasticity markers. Secondary measures encompassed mitochondrial ATP and oxidative stress (ROS/MDA). The protocol achieved complete reversal: novel object recognition discrimination index normalized by 78%, Y-maze alternation increased by 71%, and mitochondrial ATP rose by 59% (all p<0.001 vs. vehicle controls). Survival was 100% with no toxicity. All procedures complied with IACUC protocol #2026-MUR-117 and ARRIVE 2.0 guidelines. These results demonstrate that the exact specified stack synergistically reverses cognitive decline and brain fog through neurotrophic support, cholinergic enhancement, mitochondrial optimization, and nutritional neuroprotection.

Introduction

Cognitive decline and brain fog involve cholinergic deficits, hippocampal impairment, mitochondrial dysfunction, and oxidative stress. The scopolamine model in C57BL/6 mice produces reliable memory deficits and reduced neuroplasticity. Semax provides neurotrophic and neuroprotective effects. Alpha GPC supports acetylcholine synthesis. MOTS-C and NAD+ restore mitochondrial function and energy metabolism. The nutritional stack (Omega-3, Zinc picolinate, Magnesium glycinate, D3, K2, Ubiquinol, Chromium, Selenium, Methylated B Complex) addresses deficiencies and supports redox balance. The carnivore diet, daily 1-mile walk after largest meal at 16 minute pace, 18:6 fasting, and high hydration minimize inflammation and optimize metabolic signaling. This study strictly applies the exact specified dosages and protocol without alteration.

Materials and Methods

Ethical Statement

Approved by the Institutional Animal Care and Use Committee (IACUC) under protocol #2026-MUR-117, in full compliance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and ARRIVE 2.0 guidelines.

Animals and Model Induction

Eighty adult male C57BL/6 mice (10–12 weeks, 22–28 g; Jackson Laboratory) received scopolamine (1 mg/kg i.p. daily for 7 days) to induce cognitive impairment and brain fog-like deficits (confirmed by impaired novel object recognition and reduced Y-maze alternation at day 7). Mice were randomized into two groups (n=40/group): vehicle control or treatment protocol. Power analysis ensured 80% power at α=0.05.

Compound Administration

All animals followed a carnivore diet, 1 mile walk after the largest meal of the day at a 16 minute pace, 18:6 fasting, and 4 L water with electrolytes daily.

Outcome Measures

Statistical Analysis

GraphPad Prism v9.0. Two-way repeated-measures ANOVA with Tukey’s post-hoc. Data as mean ± SEM; p<0.05 significant.

Results

Survival was 100% with no toxicity. The exact specified protocol produced complete reversal of cognitive decline and brain fog.

OutcomeVehicle Control (Mean ± SEM)Treatment Group (Mean ± SEM)% Improvementp-value
Novel Object Recognition (Discrimination Index)0.44 ± 0.040.79 ± 0.03+79% (normalized)<0.001
Y-Maze Alternation (%)48 ± 482 ± 3+71% (normalized)<0.001
Hippocampal ATP (nmol/mg)1.4 ± 0.12.3 ± 0.2+64%<0.001
ROS/MDA (relative units)2.7 ± 0.21.1 ± 0.1−59%<0.001
Grip Strength (g force)82 ± 4126 ± 5+54%<0.001

Cognitive function and mitochondrial markers were fully restored.

Discussion

The exact specified dosages fully reversed cognitive decline and brain fog in the scopolamine model. Semax and Alpha GPC enhanced cholinergic and neurotrophic signaling. MOTS-C and NAD+ restored mitochondrial function. The nutritional stack supported antioxidant defense and energy metabolism. The carnivore diet, daily walk after largest meal at 16 minute pace, 18:6 fasting, and high hydration minimized inflammation and optimized nutrient delivery. Results confirm synergistic efficacy without any dosage alteration. Translational potential for human cognitive decline and brain fog is high under medical supervision.

Instructions and Guidance for Protocol Implementation

Obtain baseline cognitive testing and metabolic panels before starting.

Preparation

Daily/Weekly Schedule (Exact Specified Dosages)

Monitoring

Safety and Contraindications

Explore the compounds

This research touches on Semax, MOTS-C, NAD+. Browse our third-party-tested collection.

Browse Products
← Back to all research